Patterns of oxycodone controlled release use in older people with cancer following public subsidy of oxycodone/naloxone formulations: An Australian population-based study.

Daniels, B; Luckett, T; Holliday, S; Liauw, W; Lovell, M; Phillips, J; Rowett, D; John, TN; Tervonen, H; Pearson, S-A

Patterns of oxycodone controlled release use in older people with cancer following public subsidy of oxycodone/naloxone formulations: An Australian population-based study.

Daniels, B Luckett, T

Holliday, S Liauw, W Lovell, M

Phillips, J

Rowett, D John, TN Tervonen, H Pearson, S-A

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: Asia Pacific Journal of Clinical Oncology, 2021, 17, (1), pp. 68-78
Issue Date:: 2021-02

Closed Access

	Filename	Description	Size
	Asia-Pac J Clncl Oncology - 2020 - Daniels - Patterns of oxycodone controlled release use in older people with cancer.pdf	Published Version	506.3 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Daniels, B
dc.contributor.author	Luckett, T https://orcid.org/0000-0001-6121-5409
dc.contributor.author	Holliday, S
dc.contributor.author	Liauw, W
dc.contributor.author	Lovell, M https://orcid.org/0000-0002-1407-2748
dc.contributor.author	Phillips, J https://orcid.org/0000-0002-3691-8230
dc.contributor.author	Rowett, D
dc.contributor.author	John, TN
dc.contributor.author	Tervonen, H
dc.contributor.author	Pearson, S-A
dc.date.accessioned	2021-12-17T01:43:13Z
dc.date.available	2020-05-28
dc.date.available	2021-12-17T01:43:13Z
dc.date.issued	2021-02
dc.identifier.citation	Asia Pacific Journal of Clinical Oncology, 2021, 17, (1), pp. 68-78
dc.identifier.issn	1743-7555
dc.identifier.issn	1743-7563
dc.identifier.uri	http://hdl.handle.net/10453/152384
dc.description.abstract	Aim Public subsidy of the oxycodone/naloxone controlled release (CR) combination in December 2011 expanded the overall market for oxycodone CR in the general public in Australia; we evaluate its impact in people with cancer. Methods We used Repatriation Pharmaceutical Benefits dispensing data linked with the NSW Cancer Registry for Department of Veterans’ Affairs (DVA) healthcare card holders 65 years and older residing in NSW between 2004 and 2013 to identify clients with cancer and their opioid dispensings. We used interrupted time series analysis to model changes in monthly rates of oxycodone CR tablets dispensed and initiations. We performed a retrospective cohort study to examine changes in client characteristics and opioid utilization over time by comparing clients initiating oxycodone CR before and after subsidy. Results The rate of oxycodone CR tablets dispensed/month increased by 20% from December 2011, due to uptake of the oxycodone/naloxone CR combination; monthly initiations increased immediately by 17%. Initiations of buprenorphine, fentanyl, and morphine declined from December 2011. DVA healthcare card holders were significantly more likely to initiate the 5 mg oxycodone CR formulation; more likely to use immediate release oxycodone in the 90 days following initiation; and less likely to use a weak opioid in the 90 days preceding oxycodone CR initiation following December 2011 than they were prior to that time. Conclusions The public subsidy of the oxycodone/naloxone CR formulation expanded the overall oxycodone CR market for DVA healthcare card holders with cancer. Our findings highlight the need for updated guidelines around risk management for opioid treatment in patients with cancer.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation	http://purl.org/au-research/grants/nhmrc/1060407
dc.relation.ispartof	Asia Pacific Journal of Clinical Oncology
dc.relation.isbasedon	10.1111/ajco.13408
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1112 Oncology and Carcinogenesis
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Australia
dc.subject.mesh	Delayed-Action Preparations
dc.subject.mesh	Drug Combinations
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Male
dc.subject.mesh	Naloxone
dc.subject.mesh	Neoplasms
dc.subject.mesh	Oxycodone
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Oxycodone
dc.subject.mesh	Naloxone
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Delayed-Action Preparations
dc.subject.mesh	Drug Combinations
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Australia
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Australia
dc.subject.mesh	Delayed-Action Preparations
dc.subject.mesh	Drug Combinations
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Male
dc.subject.mesh	Naloxone
dc.subject.mesh	Neoplasms
dc.subject.mesh	Oxycodone
dc.subject.mesh	Retrospective Studies
dc.title	Patterns of oxycodone controlled release use in older people with cancer following public subsidy of oxycodone/naloxone formulations: An Australian population-based study.
dc.type	Journal Article
utslib.citation.volume	17
utslib.location.activity	Australia
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2021-12-17T01:43:12Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	17
utslib.citation.issue	1

Abstract:

Aim Public subsidy of the oxycodone/naloxone controlled release (CR) combination in December 2011 expanded the overall market for oxycodone CR in the general public in Australia; we evaluate its impact in people with cancer. Methods We used Repatriation Pharmaceutical Benefits dispensing data linked with the NSW Cancer Registry for Department of Veterans’ Affairs (DVA) healthcare card holders 65 years and older residing in NSW between 2004 and 2013 to identify clients with cancer and their opioid dispensings. We used interrupted time series analysis to model changes in monthly rates of oxycodone CR tablets dispensed and initiations. We performed a retrospective cohort study to examine changes in client characteristics and opioid utilization over time by comparing clients initiating oxycodone CR before and after subsidy. Results The rate of oxycodone CR tablets dispensed/month increased by 20% from December 2011, due to uptake of the oxycodone/naloxone CR combination; monthly initiations increased immediately by 17%. Initiations of buprenorphine, fentanyl, and morphine declined from December 2011. DVA healthcare card holders were significantly more likely to initiate the 5 mg oxycodone CR formulation; more likely to use immediate release oxycodone in the 90 days following initiation; and less likely to use a weak opioid in the 90 days preceding oxycodone CR initiation following December 2011 than they were prior to that time. Conclusions The public subsidy of the oxycodone/naloxone CR formulation expanded the overall oxycodone CR market for DVA healthcare card holders with cancer. Our findings highlight the need for updated guidelines around risk management for opioid treatment in patients with cancer.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/152384